Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Feces metagenome

ABSTRACT: Probiotics and the metabolites ameliorate the symptom of inflammatory bowel diseases

PROVIDER: PRJNA809042 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18093200_1.fastq.gz	Fastqsanger.gz
	SRR18093200_2.fastq.gz	Fastqsanger.gz
	SRR18093300_1.fastq.gz	Fastqsanger.gz
	SRR18093300_2.fastq.gz	Fastqsanger.gz
	SRR18093201_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 282

Similar Datasets

Metagenome sequencing of feces of mouse treated D-galactose or not

Project description:D-galactose orally intake ameliorate DNCB-induced atopic dermatitis by modulating microbiota composition and quorum sensing. The increased abundance of bacteroidetes and decreased abundance of firmicutes was confirmed. By D-galactose treatment, Bacteroides population was increased and prevotella, ruminococcus was decreased which is related to atopic dermatitis.

2022-04-29 | E-MTAB-11632 | biostudies-arrayexpress

human oral metagenome

Project description:Salivary microbiome associated with inflammatory bowel diseases

| PRJNA414682 | ENA

feces metagenome

Project description:Bowel Preparation-Induced Microbial Dysbiosis and Its Restoration by Probiotics in Ulcerative Colitis

| PRJNA1280080 | ENA

human gut metagenome

Project description:Discovery of disease-adapted bacterial lineages in inflammatory bowel diseases

| PRJNA993675 | ENA

Identification of pathways and transcription factors relevant to gut inflammation and anti-inflammatory probiotics

Project description:Using Affymetrix data analysis, important signalling pathways and transcription factors relevant to gut inflammation and anti-inflammatory action of probiotics were identified using the clinically validated probiotic VSL#3 and the IL10-knockout mouse, an animal model for inflammatory bowel disease. VSL#3 increased expression of genes involved in PPAR signalling and metabolism of xenobiotics and decreased expression of genes involved in immune response/inflammatory response.

2009-07-29 | GSE13819 | GEO

Lactic acid bacteria derived bacteriocin targets purine and histidine metabolisms of gut microbiota to alleviate colitis

Project description:Gut microbiota is an unignored target in maintaining intestinal homeostasis due to its regulatory effects on intestinal health through multiple mechanisms, including enhancing intestinal barriers, modulating microbial diversity, secreting various metabolites, etc. Bacteriocins produced by probiotics have been gradually proved vital for intestinal diseases intervention, however, the corresponding mechanisms have received less attention and the whole story of their regulative activities are hard to be fully uncovered. The two-peptide Plantaricin NC8 (PLNC8), coded by gene plnc8, is a bacteriocin ubiquitously produced by Lactobacillus plantarum, has been regarded as the potential vital bacteriocin for the anti-inflammatory effects of Lactobacillus plantarum. This study exploited CRISPR-cas9 and prokaryotic gene overexpression techniques to construct the plnc8 strains for the anti-inflammatory mechanism investigation. Based on the metagenomics, transcriptomics and metabolomics analysis, the anti-enteritis mechanism of PLNC8 systematically in DSS-induced enteritis models were comprehensively revealed. PLNC8 induced alterations in the composition of gut microbiota composition, promoting the alterations of multiple probiotics such as Eubacterium plexicaudatum, Doreasp.5-2, Enterococcus cecorum and Prevotella oulorum. Besides, various metabolites produced by the gut microbiota were influenced, and the key metabolites of xanthine, hypoxanthine, and L-histidine were regulated via purine and histidine metabolic pathways. These metabolites further inhibited p38 MAPK phosphorylation of enterocytes induced by DSS. Ultimately, the intestinal barrier repairment and anti- enteritis were achieved, proving the anti-enteritis effects of PLNC8 via microbe-metabolites-enterocyte axis.

2024-08-20 | GSE274981 | GEO

Therapeutic Effects of Valeriana jatamansi on Ulcerative Colitis: Insights into Mechanisms of Action through Metabolomics and Microbiome Analysis

Project description:Ulcerative colitis (UC), belonging to inflammatory bowel disease (IBD), is a chronic and relapsing inflammatory disorders of the gastrointestinal tract, which is not completely cured so far. Valeriana jatamansi is a Chinese medicine used clinically to treat "diarrhea", which is closely related to UC. This study was to elucidate the therapeutic effects of V. jatamansi extract (VJE) on dextran sodium sulfate (DSS)-induced UC in mice and its underlying mechanism. In this work, VJE effectively ameliorate the symptoms, histopathological scores and reduce the production of inflammatory factors of UC mice. The colon untargeted metabolomics analysis and 16S rDNA sequencing showed remarkable differences in colon metabolite profiles and intestinal microbiome composition between the control and DSS groups, and VJE intervention can reduce these differences. Thirty-two biomarkers were found and modulated the primary pathways including pyrimidine metabolism, arginine biosynthesis and glutathione metabolism. Meanwhile, twelve significant taxa of gut microbiota were found. Moreover, there is a close relationship between endogenous metabolites and intestinal flora. These findings suggested that VJE ameliorates UC by inhibiting inflammatory factors, recovering intestinal maladjustment, and regulating the interaction between intestinal microbiota and host metabolites. Therefore, the intervention of V. jatamansi is a potential therapeutic treatment for UC.

2023-07-24 | PXD043047 | Pride

Feces amplicons

Project description:Prediction of irritable bowel syndrome by integrating urine metabolites and gut microbiota

| PRJNA1242706 | ENA

Project description:Dietary Fibers Promote Inflammation in Inflammatory Bowel Diseases

| PRJNA690735 | ENA

Project description:Guiding longitudinal sampling in inflammatory bowel diseases cohorts

| PRJEB23009 | ENA